Qt Imaging Holdings, Inc. · NASDAQ:QTI

Qt Imaging — Investor Presentation (December 2024)

63 slides from Qt Imaging's investor presentation, December 2024

Slide 1: Quantitative Transmission Imaging Investor Presentation
Quantitative Transmission Imaging Breast Acoustic CT Scanner INVESTOR PRESENTATION December 2024
Slide 2: Disclaimer
Disclaimer ABOUT THIS PRESENTATION This investor presentation (this “Presentation”) is provided for informational purposes only. The information contained herein does not purport to be all-inclusive and neither QT Imaging Holdings, Inc. (the “Company”, “QT Imaging Holdings”, “QTI”), nor its respecti
Slide 3: Disclaimer: Forward Looking Statements
Disclaimer FORWARD LOOKING STATEMENTS Certain statements included in this Presentation that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generall
Slide 4: Disclaimer: Non-GAAP Financial Measures
Disclaimer NON-GAAP FINANCIAL MEASURES This presentation includes references to EBITDA and Adjusted EBITDA, financial measures that have not been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). EBITDA is defined as loss before interest expense, inc
Slide 5: QT Imaging Holdings Has the Potential to Transform Medical Imaging
QT Imaging Holdings (QTI) Has the Potential to Transform Medical Imaging • QTI is a medical device company with imaging technology that has the potential to transform the industry • QTI Scanner is the only 3D imaging device to receive FDA clearance for use as a transmission and reflection ultrasonic
Slide 6: Our Mission
Our Mission • Create disruptive innovation using technology (software, NIH has machine learning, and smart physics) to improve medical imaging awarded QT and thus, healthcare quality and access Imaging about • Continue to build upon our FDA clearances to offer QTI as a $18M breast screening imaging
Slide 7: Introduction to the QT Imaging Holdings Management Team
Introduction to the QT Imaging Holdings Management Team Nasser C. Bilal Malik, Dr. Raluca Dinu Stas Budagov Steve Choate Pirshafiey, MBA Ph.D. CHIEF EXECUTIVE CHIEF FINANCIAL CHIEF OPERATING CHIEF PRODUCT CHIEF SCIENCE OFFICER OFFICER OFFICER OFFICER OFFICER Dr. Raluca Dinu is a global Mr. Budagov i
Slide 8: Executive Summary
Executive Summary Patent-protected technology: 14 granted patents in US/Europe + 2 new patent applications TECHNOLOGICAL CONSIDERATIONS PATIENT CONSIDERATIONS • FDA cleared for breast Imaging • Safe, no radiation, no contrast ➢ Breakthrough Device Designation awarded by the FDA provides • No discomf
Slide 9: Distribution Agreement with NXC Imaging
Distribution Agreement with NXC Imaging A Subsidiary of Canon Medical Systems • Under Distribution Agreement with NXC Imaging for US market • Accessing NXC Imaging's distribution channel in the US and the US territories, this agreement provides potential to accelerate the commercial roll-out of QTI’
Slide 10: Successful Completion of Feasibility Study with Canon Medical Systems
Successful Completion of Feasibility Study with Canon Medical Systems • Canon evaluated the business, technical, and clinical values of QTI’s ultrasound breast scanner including: −product quality validation −development and manufacturing studies −clinical evaluation −regulatory investigation −market
Slide 11: Participation at RSNA 2024
Participation at RSNA 2024 “Assessing Non-Inferiority of QT Imaging Compared with DBT: Results from a MRMC Observer Study” – Dr. Bilal Malik Copyright ©2024 QT Imaging, Holdings, Inc. All Rights Reserved. 11
Slide 12: Breast Health
gy QT IMAGING BREAST HEALTH
Slide 13: QTI's Technology Has the Opportunity to Transform Several Large Markets
QTI’s Technology Has the Opportunity to Transform Several Large Markets 2023 GLOBAL MEDICAL IMAGING MARKET SIZE: $40B(1) Current Market Future Markets – Body Scanner Platform Development IMAGE-GUIDED PROCEDURES: BREAST: $5B MARKET(2) ORTHO: $9B MARKET(3) INFANT: $8B MARKET (4) $5B MARKET(5) • FDA ap
Slide 14: Other Ultrasound Products Use 2D Imaging for Dense Breast Screening
Other Ultrasound Products Use 2D Imaging for Dense Breast Screening DELPHINUS BREAST INVENIA ABUS ACUSON S2000 ABVS AWBUS SOFIA 3D SOFTVUE ACOUSTIC CT DESIGN TYPE Articulating Arm Articulating Arm Articulating Arm Rotating Armature Water Bath Water Bath Guided Handheld OUTPUT Stacked 2D Stacked 2D S
Slide 15: Current Ultrasound Technologies Have Major Deficiencies
Current Ultrasound Technologies Have Major Deficiencies Shortfalls of Commercial Current, Rival Systems(2): • Reflection images have speckle; compounding without refraction correction • No valid true “transmission” mode – use “shear wave” (low resolution) data (ABUS, AVUS, etc. are not transmission)
Slide 16: The QT Scanner Delivers a Better Experience for Patients
The QT Scanner Delivers a Better Experience for Patients than Traditional Systems HANDHELD QT IMAGING ULTRASOUND MRI MAMMOGRAPHY Image Quality Safety(1) Speed Cost Efficiency Patient Experience …OVER HHUS …OVER MRI ...OVER MAMMOGRAPHY The QTI • Superior image quality • High resolution and • Improved
Slide 17: QT Imaging's FDA-cleared Solution for Dense Breasts
QT Imaging’s FDA-cleared Solution for Dense Breasts Many Women Have Dense Breasts, The FDA Has Recognized the Which Mammograms are Inefficient Importance of Breast Density in Screening for Cancer in Breast Cancer Screening 50% of women between 50% 50% the ages of 40-74 in the US have dense breasts(1
Slide 18: Clinical Evidence: Non-Inferiority to DBT
Clinical Evidence: Non-Inferiority to DBT Non-inferiority to DBT ROC curves Individual reader AUC • Breast Abnormalities The line closer to 1.0 is The line closer to 1.0 is indicative of higher accuracy indicative of higher accuracy • Benign, non-cancer, normal without biopsy • Cancer, abnormal with
Slide 19: Sensitivity and Specificity
Sensitivity and Specificity • Sensitivity − Lower for QT (70.6%) compared to DBT (85.2%) − Potentially attributable to reader unfamiliarity with QT imaging, suggesting a need for enhanced training • Specificity − Significantly higher for QT (60.1%) compared to DBT (37.2%) − Indicates QT's ability to
Slide 20: Subgroup Analysis: Dense Breasts
Subgroup Analysis: Dense Breasts • Both sensitivity and specificity of DBT are dependent on breast density • Specificity of QT is independent of breast density Copyright ©2024 QT Imaging, Inc. All Rights Reserved. 20
Slide 21: Clinical Evidence: Anatomic & Visual Grade with Comparative Modality
Clinical Evidence: Anatomic & Visual Grade with Comparative Modality Normal Anatomic Comparison X-Ray Mammography (XRM) Handheld Ultrasound (HHUS) • Visual Graded Analysis • 4 readers • 5 readers • Compared QTI V/s HHUS, • 22 breast , 20 subjects • 17 breast , 17 subjects XRM • Lower score means bet
Slide 22: The Current Breast Imaging Paradigm Leads to Unnecessary Concern and Costs
The Current Breast Imaging Paradigm Leads to Unnecessary Concern and Costs Screening compliance is low For every 1,000 screening mammograms: 35% of women aged 40–70 do not get screened.(1) CALL BACK 35% RATES 98% of 65% Do not follow guidelines ~15% call-backs rates with 150 Recalls are Avoidable Fo
Slide 23: Clinical Evidence: Recall Rate
Clinical Evidence Recall Rate • Recall Rates: 10% Approximately 150 women out of Combined Recall Rate every 1,000 screened are recalled for more tests. Out of those 150, • Adherence to screening only three or four will be diagnosed with cancer. compliance: Unnecessary recalls create stress − 16% Dec
Slide 24: Technology and Clinical Overview
TECHNOLOGY AND CLINICAL OVERVIEW
Slide 25: Quantitative Transmission (QT) Imaging
Quantitative Transmission (QT) Imaging • What is QT Imaging? − Inherently 3D volumetric ultrasound modality due to 3D data acquisition and image reconstruction − Uses CT-like configuration with ultrasound to acquire and reconstruct transmission images which map the speed-of-sound across the tissue v
Slide 26: Optimized Patient Experience
Optimized Patient Experience • No ionized radiation. Acoustic source only. • No breast compression and associated discomfort. • 10-12 minutes per breast exam time. • Quiet and comfortable (as compared to MRI - claustrophobia, coil pressure, noise and lengthy exams). • No contrast injection or associ
Slide 27: QTI Provides High Resolution, Similar to MRI
QTI Provides High Resolution, Similar to MRI MRI Spiral data QTI (3D UT) Planar acquisition Volumetric 20mm for speed of overlapping acquisition detectors 2mm gap Receiver Array Receiver Array Data points per voxel ~200,000 Data points per voxel ~180 thousand data points (1) times more data ~36 bill
Slide 28: Technical Capabilities
Technical Capabilities • Resolution of ~600 microns in reflection compared to 800 microns(1) for MRI (depends on field strength, homogeneity etc) • Contrast to noise ratio of 23:1 at 100 microns ( in reflection; can detect small calcifications) • Contrast to noise ratio of 15:1 (at resolution in tra
Slide 29: Enhanced Clinical Capabilities and Value
Enhanced Clinical Capabilities and Value • High-quality and high-resolution native 3D Imaging • Quantifiable images enables accurate analysis, comparison and trending • Consistent and reproduceable image quality regardless of operator or breast size/tissue type • Clinical feature detection of 50-100
Slide 30: Imaging Accuracy in Breast Mass Diagnosis
Imaging Accuracy in Breast Mass Diagnosis(1) QT IMAGING XRM HHUS CE-MRI Normal Breast Dense Breast Cyst Tumor Solid Tumor Calcification (1) Based on opinion of QT Imaging Holdings team.. Copyright ©2024 QT Imaging, Holdings, Inc. All Rights Reserved. 30
Slide 32: Modality Comparison – FFDM and HHUS
Modality Comparison – FFDM and HHUS Mammogram - (left) CC and (right) MLO views Arrows mark a region of spiculated focal asymmetry HHUS images across the lesion Copyright ©2024 QT Imaging, Inc. All Rights Reserved. 32
Slide 33: Modality Comparison – MRI Images
Modality Comparison – MRI Images Non-fat sat Pre-contrast Fast low angle Post-contrast shot 3D (FL3D) Copyright ©2024 QT Imaging, Inc. All Rights Reserved. 33
Slide 34: Modality Comparison – QT Image
Modality Comparison – QT Image QT speed of sound image showing the mass (marked by arrows) as a region of high-speed IDC in lower outer quadrant of the left breast, 4 o’clock in the coronal view. Copyright ©2024 QT Imaging, Inc. All Rights Reserved. 34
Slide 35: QTI Scans Image Quality
gy QT IMAGING QTI SCANS IMAGE QUALITY
Slide 36: Normal Dense Breast
Normal Dense Breast CORONAL AXIAL SAGITTAL Transmission Chest wall Reflection click on image for video Dense breast – no high-speed lesion, mass, or cancer Copyright ©2024 QT Imaging, Holdings, Inc. All Rights Reserved. 36
Slide 37: Cyst Identification Using Speed of Sound
Cyst Identification Using Speed of Sound Cystic mass seen in speed of sound (top 3 panels) and anechoic in reflection (bottom 3 panels) in 3 planes – coronal, axial, and sagittal Copyright ©2024 QT Imaging, Holdings, Inc. All Rights Reserved. 37
Slide 38: Solid Identification Using Speed of Sound
Solid Identification Using Speed of Sound Solid mass seen in speed of sound (top 3 panels) and hypoecoic in reflection (bottom 3 panels) in 3 planes – coronal, axial and sagittal Copyright ©2024 QT Imaging, Holdings, Inc. All Rights Reserved. 38
Slide 39: Case 1: Invasive Ductal Carcinoma
Case 1: Invasive Ductal Carcinoma Mammogram - (left) CC and (right) MLO views Arrows mark a region of spiculated focal asymmetry HHUS images across the lesion Copyright ©2024 QT Imaging, Holdings, Inc. All Rights Reserved. 39
Slide 41: Case 1: QTI Scan
Case 1: QTI Scan QT speed of sound image showing the mass (marked by arrows) as a region of high-speed IDC in lower outer quadrant of the left breast, 4 o’clock in the coronal view. Copyright ©2024 QT Imaging, Holdings, Inc. All Rights Reserved. 41
Slide 43: Case 2: QTI Speed of Sound
Case 2: QTI Speed of Sound QT speed of sound image showing the mass (marked by arrows) as a region of high-speed. In coronal view at 8 o’clock. Relatively posterior mass but still all visible in the QT image. Copyright ©2024 QT Imaging, Holdings, Inc. All Rights Reserved. 43
Slide 45: Case 3: QTI Speed of Sound
Case 3: QTI Speed of Sound QT speed of sound image showing the mass (marked by arrows) as a region of high-speed. In coronal view, at 6 o’clock, near the center. Copyright ©2024 QT Imaging, Holdings, Inc. All Rights Reserved. 45
Slide 46: Calcifications Detected with Better Visibility Than XRM
Calcifications Detected with Better Visibility Than XRM Digital Mammography QT Reflection Tomogram Detectability of calcifications in QT Acoustic CT is superior to XRM (1) (1) Sensitivity of Quantitative Transmission ultrasound to detection of microcalcifications. SPIE (International Society for Opt
Slide 47: Market Positioning and QT Scanner Locations in US
MARKET POSITIONING AND QT SCANNER LOCATIONS IN US
Slide 48: Market Positioning of Breast Acoustic CT Scanner
Market Positioning of Breast Acoustic CT Scanner Not intended to compete with mammography for screening, although many patients may find it preferrable for: • Dense breasts • Implants • Post therapy screening where breasts can be sensitive to compression • When concerned about radiation dose Diagnos
Slide 50: Open Angle Scanner
gy QT IMAGING OPEN ANGLE SCANNER
Slide 51: Developing an Open Angle Scanner Will Expand the Technology to New Markets
Developing an Open Angle Scanner Will Expand the Technology to New Markets …providing significant potential to access new markets and applications • The Open Angle Scanner uses an open, partial angle configuration which reduces the viewing field from 3600 to 3250 and provides additional capabilities
Slide 52: Q3'24 and YTD Ending 09/30/24 Financials
Q3’ 24 AND YTD ENDING 09/30/24 FINACIALS
Slide 53: Financial Highlights for Q3'24 QTD and YTD Ending 09/30/24
Financial Highlights for Q3’24 QTD and YTD Ending 09/30/24 • Commercial revenue was $1.0 million during the third quarter of 2024, compared to $1.7 million during the second quarter of 2024 and less than $0.1 million during the third quarter of 2023. • Commercial revenue was $4.0 million for the nin
Slide 54: Financial Highlights for Q3'24 QTD and YTD Ending 09/30/24
Financial Highlights for Q3’24 QTD and YTD Ending 09/30/24 • Net loss of $3.6 million for the third quarter of 2024, compared to net loss of $1.4 million for the third quarter in 2023. Q3’24 net loss includes: ➢ $0.1 million of net non-cash income related to the change in fair value of the warrant,
Slide 57: Adjustments to EBITDA
Adjustments to EBITDA (1) The decrease in fair value of warrant liability during the three and nine months ended September 30, 2024 relates to the liability classified private placement warrants to reflect the decrease of the publicly traded price per warrant. Additional expense related to the modif
Slide 61: Summary of YTD Ending 09/30/24 and YTD Ending 09/30/23 Cash Flow Results
Summary of YTD Ending 09/30/24 and YTD Ending 09/30/23 Cash Flow Results Copyright ©2024 QT Imaging, Inc. All Rights Reserved. 61
Slide 62: Investment Highlights
Investment Highlights Cutting-edge imaging technology with multiple potential applications creates a tremendous opportunity to transform the imaging market Industry-Transforming, NXC Imaging Distribution FDA Cleared (with Agreement to Drive awarded Breakthrough Accelerated Commercial Roll- Device De
Slide 63: Thank You!
gy QT IMAGING Thank You!

QT Imaging Holdings — Investor Presentation (December 2024) on 6ix

Qt Imaging — Investor Presentation (December 2024)

Slide 1: Quantitative Transmission Imaging Investor Presentation

Slide 2: Disclaimer

Slide 3: Disclaimer: Forward Looking Statements

Slide 4: Disclaimer: Non-GAAP Financial Measures

Slide 5: QT Imaging Holdings Has the Potential to Transform Medical Imaging

Slide 6: Our Mission

Slide 7: Introduction to the QT Imaging Holdings Management Team

Slide 8: Executive Summary

Slide 9: Distribution Agreement with NXC Imaging

Slide 10: Successful Completion of Feasibility Study with Canon Medical Systems

Slide 11: Participation at RSNA 2024

Slide 12: Breast Health

Slide 13: QTI's Technology Has the Opportunity to Transform Several Large Markets

Slide 14: Other Ultrasound Products Use 2D Imaging for Dense Breast Screening

Slide 15: Current Ultrasound Technologies Have Major Deficiencies

Slide 16: The QT Scanner Delivers a Better Experience for Patients

Slide 17: QT Imaging's FDA-cleared Solution for Dense Breasts

Slide 18: Clinical Evidence: Non-Inferiority to DBT

Slide 19: Sensitivity and Specificity

Slide 20: Subgroup Analysis: Dense Breasts

Slide 21: Clinical Evidence: Anatomic & Visual Grade with Comparative Modality

Slide 22: The Current Breast Imaging Paradigm Leads to Unnecessary Concern and Costs

Slide 23: Clinical Evidence: Recall Rate

Slide 24: Technology and Clinical Overview

Slide 25: Quantitative Transmission (QT) Imaging

Slide 26: Optimized Patient Experience

Slide 27: QTI Provides High Resolution, Similar to MRI

Slide 28: Technical Capabilities

Slide 29: Enhanced Clinical Capabilities and Value

Slide 30: Imaging Accuracy in Breast Mass Diagnosis

Slide 31: QT Speed of Sound and Reflection Images

Slide 32: Modality Comparison – FFDM and HHUS

Slide 33: Modality Comparison – MRI Images

Slide 34: Modality Comparison – QT Image

Slide 35: QTI Scans Image Quality

Slide 36: Normal Dense Breast

Slide 37: Cyst Identification Using Speed of Sound

Slide 38: Solid Identification Using Speed of Sound

Slide 39: Case 1: Invasive Ductal Carcinoma

Slide 40: Case 1: MRI

Slide 41: Case 1: QTI Scan

Slide 42: Case 2: MRI – Invasive Ductal Carcinoma

Slide 43: Case 2: QTI Speed of Sound

Slide 44: Case 3: MRI – Invasive Ductal Carcinoma

Slide 45: Case 3: QTI Speed of Sound

Slide 46: Calcifications Detected with Better Visibility Than XRM

Slide 47: Market Positioning and QT Scanner Locations in US

Slide 48: Market Positioning of Breast Acoustic CT Scanner

Slide 49: QT Scanner Locations Map

Slide 50: Open Angle Scanner

Slide 51: Developing an Open Angle Scanner Will Expand the Technology to New Markets

Slide 52: Q3'24 and YTD Ending 09/30/24 Financials

Slide 53: Financial Highlights for Q3'24 QTD and YTD Ending 09/30/24

Slide 54: Financial Highlights for Q3'24 QTD and YTD Ending 09/30/24

Slide 55: Summary of Q3 QTD and YTD Ending 09/30/24 GAAP Results

Slide 56: Summary of Q3 QTD and YTD Ending 09/30/24 Non-GAAP Results

Slide 57: Adjustments to EBITDA

Slide 58: Summary of Q3'24 QTD and Q3'23 QTD P&L Results

Slide 59: Summary of YTD Ending 09/30/24 and YTD Ending 09/30/23 P&L Results

Slide 60: Summary of Q3'24 QTD and Q3'23 QTD Cash Flow Results

Slide 61: Summary of YTD Ending 09/30/24 and YTD Ending 09/30/23 Cash Flow Results

Slide 62: Investment Highlights

Slide 63: Thank You!